RESUMO
CASO CLÍNICO: Mujer de 73 años en tratamiento con escitalopram que presentó glaucoma agudo de ángulo cerrado secundario a efusión uveal tras duplicar la dosis de dicho fármaco 3 días antes. Evolucionó favorablemente tras la suspensión del antidepresivo además de tratamiento hipotensor tópico y prednisona vía oral. DISCUSIÓN: La efusión uveal secundaria a fármacos es un síndrome infrecuente. Se puede acompañar de miopización y glaucoma agudo por cierre angular. El diagnóstico correcto y la suspensión del fármaco conducen a la resolución de esta nosología
CASE REPORT: A 73 year-old woman with depression treated with escitalopram developed acute secondary angle closure glaucoma related to uveal effusion after duplicating the drug dose 3 days before. She evolved favorably once the antidepressant treatment was suspended and a new treatment with topical hypotensive therapy and oral prednisone was used. DISCUSSION: The uveal effusion syndrome associated to medicines is rare; it may be associated with acute myopic shift and acute angle closure glaucoma. The correct diagnosis and discontinuation of the drug lead to the resolution of this nosology
Assuntos
Adulto , Feminino , Humanos , Doenças da Úvea/induzido quimicamente , Antidepressivos/efeitos adversos , Miopia/induzido quimicamente , Glaucoma/induzido quimicamente , Cefaleia/etiologiaRESUMO
CASE REPORT: A 73 year-old woman with depression treated with escitalopram developed acute secondary angle closure glaucoma related to uveal effusion after duplicating the drug dose 3 days before. She evolved favorably once the antidepressant treatment was suspended and a new treatment with topical hypotensive therapy and oral prednisone was used. DISCUSSION: The uveal effusion syndrome associated to medicines is rare; it may be associated with acute myopic shift and acute angle closure glaucoma. The correct diagnosis and discontinuation of the drug lead to the resolution of this nosology.
Assuntos
Citalopram/efeitos adversos , Glaucoma de Ângulo Fechado/induzido quimicamente , Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos , Líquido Sub-Retiniano , Doenças da Úvea/induzido quimicamente , Doença Aguda , Idoso , Atropina/uso terapêutico , Tartarato de Brimonidina/uso terapêutico , Doenças da Coroide/induzido quimicamente , Doenças da Coroide/tratamento farmacológico , Corpo Ciliar/patologia , Overdose de Drogas , Emergências , Feminino , Glaucoma de Ângulo Fechado/tratamento farmacológico , Humanos , Miopia/induzido quimicamente , Prednisona/uso terapêutico , Receptores de Serotonina/efeitos dos fármacos , Receptores de Serotonina/fisiologia , Líquido Sub-Retiniano/diagnóstico por imagem , Timolol/uso terapêutico , Doenças da Úvea/tratamento farmacológico , Doenças da Úvea/fisiopatologiaRESUMO
Caso clínico: Mujer de 64 años en tratamiento con amantadina durante 2 años por enfermedad de Parkinson, que presentó edema corneal bilateral de inicio brusco. Inicialmente se trató como una endotelitis herpética sin mejoría, al desconocer la medicación empleada por la enferma. Finalmente el edema se resolvió tras la suspensión del fármaco. Discusión: El hidrocloruro de amantadina puede producir disfunción endotelial. El edema corneal puede ser reversible tras su suspensión, pero la densidad endotelial permanece baja. Sería necesario realizar un control oftalmológico previo al inicio del tratamiento para valorar el riesgo/beneficio del mismo, sobre todo en los pacientes que presenten baja densidad endotelial o un endotelio alterado (AU)
Case report: A 64 year-old female with Parkinson disease treated with amantadine for two years who suddenly suffered bilateral corneal oedema. It was initially treated as herpetic endotheliitis without improvement as we lacked information on her chronic treatment. The corneal oedema finally resolved after withdrawing the drug. Discussion: Amantadine hydrochloride may produce endothelial dysfunction. Once the amantadine treatment is stopped, the corneal oedema may be reversible but endothelial density remains low. An ophthalmologist examination should be performed before the initiation of amantadine treatment in order to establish a risk: benefit ratio, especially in those patients with low endothelial density or any endothelial anomaly (AU)
Assuntos
Humanos , Feminino , Idoso , Amantadina/efeitos adversos , Amantadina/farmacologia , Amantadina/uso terapêutico , Edema da Córnea , Relatos de CasosRESUMO
CASE REPORT: A 64 year-old female with Parkinson disease treated with amantadine for two years who suddenly suffered bilateral corneal oedema. It was initially treated as herpetic endotheliitis without improvement as we lacked information on her chronic treatment. The corneal oedema finally resolved after withdrawing the drug. DISCUSSION: Amantadine hydrochloride may produce endothelial dysfunction. Once the amantadine treatment is stopped, the corneal oedema may be reversible but endothelial density remains low. An ophthalmologist examination should be performed before the initiation of amantadine treatment in order to establish a risk: benefit ratio, especially in those patients with low endothelial density or any endothelial anomaly.
